An investigation on behalf of investors of Dimension Therapeutics Inc (NASDAQ:DMTX) in connection with the proposed takeover was announced and NASDAQ:DMTX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 10/11/2017 --An investigation on behalf of investors, who currently hold NASDAQ:DMTX shares, was announced concerning whether the takeover of Dimension Therapeutics Inc by REGENXBIO Inc for a value of approximately $3.41 per share is unfair.

Investors who purchased shares of Dimension Therapeutics Inc (NASDAQ:DMTX) and currently hold any of those NASDAQ:DMTX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain officers and directors of Dimension Therapeutics Inc breached their fiduciary duties owed to NASDAQ:DMTX investors in connection with the proposed acquisition.

On August 25, 2017, REGENXBIO Inc. (Nasdaq:RGNX) and Dimension Therapeutics Inc (NASDAQ:DMTX) announced that they have entered into an agreement under which REGENXBIO will acquire Dimension Therapeutics Inc (NASDAQ:DMTX) in an all-stock transaction for an implied value of approximately $3.41 per share. On October 3, 2017, Dimension Therapeutics Inc announced that it had signed a definitive merger agreement with Ultragenyx. Terms of the deal call for shareholders to receive $6.00 per share for each share of Dimension stock they own.

However, given that at least one analyst has set the high price target for NASDAQ:DMTX shares at $9.00 per share, the investigation concerns whether the offer is unfair to Dimension Therapeutics Inc (NASDAQ:DMTX stockholders. More specifically, the investigation concerns whether the Dimension Therapeutics Inc (NASDAQ:DMTX Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Those who are current investors in Dimension Therapeutics Inc (NASDAQ:DMTX) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com